Biogen Inc. (BIIB)
NASDAQ: BIIB
· Real-Time Price · USD
135.67
-2.00 (-1.45%)
At close: Sep 25, 2025, 3:59 PM
136.15
0.35%
After-hours: Sep 25, 2025, 05:11 PM EDT
-1.45% (1D)
| Bid | 135 |
| Market Cap | 19.89B |
| Revenue (ttm) | 10B |
| Net Income (ttm) | 1.53B |
| EPS (ttm) | 10.45 |
| PE Ratio (ttm) | 12.98 |
| Forward PE | 8.81 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 139.38 |
| Volume | 1,219,895 |
| Avg. Volume (20D) | 1,751,794 |
| Open | 138.40 |
| Previous Close | 137.67 |
| Day's Range | 135.41 - 140.67 |
| 52-Week Range | 110.04 - 197.70 |
| Beta | 0.11 |
| Ex-Dividend Date | n/a |
About BIIB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BIIB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BIIB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsBiogen Inc. is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
-0.96%
Biogen shares are trading lower after the FDA issu...
Unlock content with
Pro Subscription
3 weeks ago
+5.6%
Biogen shares are trading higher after the company announced data from Phase 1/2a and open-label extension studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome.
